COIOSDeep risk insights through multi-disciplinary research across the globe
a wall with a painting of a woman wearing a mask
Item new Preprint · not peer-reviewed Added

Rheumatic heart disease valves show B-cell activity, and rituximab is tested in children

Rheumatic mitral valves showed raised B-cell pathways, and rituximab was well tolerated in children with rheumatic heart disease in Senegal.

The study examined B cells as a possible treatment target in rheumatic heart disease (RHD). A 750-mRNA panel on rheumatic mitral valve tissue showed upregulated B-cell pathways, including CD20-associated and immunoglobulin genes. Children with RHD in Dakar, Senegal, then received rituximab in a feasibility study, and treatment was well tolerated. In a first-year safety analysis of the later randomised trial, treated children had falling anti-streptolysin O titres. They also showed clinical improvement compared with controls. The abstract gives no participant numbers or effect sizes, and the trial findings are preliminary.

Why it is interesting: No current therapy targets the autoimmune process behind rheumatic heart disease. This study links valve tissue findings to an early trial of B-cell depletion in children in Senegal.

Source
medRxiv, 17 November 2026
DOI
10.64898/2026.11.17.26367998
Type
Preprint
Design
Valve tissue transcriptomic panel (750 mRNAs) plus rituximab feasibility study and first-year interim safety analysis of an RCT in children with RHD, Dakar; n and follow-up not stated
Verdict
New finding
Driver
Innovation in treatment

Other drivers in Tomorrow's world